Immunotherapy Drugs Market

By Drug Type;

Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha & Beta, Interleukins, and Others

By Therapy Area;

Cancer, Autoimmune & Inflammatory Diseases, Infectious Diseases, and Other

By End User;

Hospitals, Clinics, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn831895064 Published Date: June, 2025 Updated Date: July, 2025

Immunotherapy Drugs Market Overview

Immunotherapy Drugs Market (USD Million)

Immunotherapy Drugs Market was valued at USD 200,016.72 million in the year 2024. The size of this market is expected to increase to USD 408,763.82 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 10.8%.


Immunotherapy Drugs Market

*Market size in USD million

CAGR 10.8 %


Study Period2025 - 2031
Base Year2024
CAGR (%)10.8 %
Market Size (2024)USD 200,016.72 Million
Market Size (2031)USD 408,763.82 Million
Market ConcentrationLow
Report Pages376
200,016.72
2024
408,763.82
2031

Major Players

  • Novartis International AG
  • Johnson & Johnson
  • Glaxosmithkline PLC
  • Amgen Inc
  • Abbvie
  • Astrazeneca
  • Bristol-Myers Squibb
  • ELI Lilly and Company

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Immunotherapy Drugs Market

Fragmented - Highly competitive market without dominant players


The Immunotherapy Drugs Market is experiencing rapid growth, primarily driven by the increasing adoption of these therapies in oncology. Immunotherapy has emerged as a critical component in modern cancer treatment, harnessing the body's immune system to target and destroy cancer cells. Currently, over 55% of advanced cancer therapies incorporate immunotherapy, reflecting its effectiveness in improving patient survival rates and quality of life with fewer side effects than conventional treatments.

Breakthroughs in Monoclonal Antibodies and Checkpoint Inhibitors
Monoclonal antibodies and checkpoint inhibitors have become pivotal in the immunotherapy landscape, representing nearly 60% of the market. These targeted therapies work by precisely modulating immune responses, enhancing their appeal for personalized cancer treatment. As a result, they have seen widespread adoption in oncology, driving significant market growth due to their ability to deliver more effective and safer outcomes.

Rising Impact of CAR-T Cell Therapies
CAR-T cell therapies, a cutting-edge approach in immunotherapy, have gained considerable traction due to their transformative potential in treating hematologic cancers. These personalized, cell-based therapies now account for approximately 20% of the immunotherapy market, offering significant benefits through precise, patient-specific cancer targeting. Their remarkable efficacy has made them a critical focus in precision medicine.

Supportive Regulatory Landscape and Research Momentum
The immunotherapy market is further bolstered by favorable regulatory frameworks and substantial research investments. Currently, over 40% of ongoing oncology clinical trials involve immunotherapy agents, highlighting the robust pipeline for next-generation treatments. This supportive environment is expected to drive the rapid approval and commercialization of innovative therapies, further accelerating market expansion.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Type
    2. Market Snapshot, By Therapy Area
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Immunotherapy Drugs Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Integration of Biomarker-driven Approaches
        2. Collaboration Between Industry and Research Institutions
        3. Regulatory Support for Immunotherapy Development
        4. Growing Healthcare Expenditure
      2. Restraints
        1. Regulatory Hurdles in Drug Approval
        2. Competition from Conventional Therapies
        3. Accessibility Issues in Developing Regions
        4. Uncertainty in Reimbursement Policies
      3. Opportunities
        1. Investment in Precision Medicine Initiatives
        2. Rising Demand for Immunotherapy Biologics
        3. Adoption of Immunotherapies in Earlier Treatment Lines
        4. Integration of Artificial Intelligence in Drug Development
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Immunotherapy Drugs Market, By Drug Type, 2021 - 2031 (USD Million)
      1. Monoclonal Antibodies
      2. Adult Vaccines
      3. Checkpoint Inhibitors
      4. Interferons Alpha & Beta
      5. Interleukins
      6. Others
    2. Immunotherapy Drugs Market, By Therapy Area, 2021 - 2031 (USD Million)
      1. Cancer
      2. Autoimmune & Inflammatory Diseases
      3. Infectious Diseases
      4. Others
    3. Immunotherapy Drugs Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Clinics
      3. Others
    4. Immunotherapy Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Novartis International AG
      2. Johnson & Johnson
      3. Glaxosmithkline PLC
      4. Amgen Inc
      5. Abbvie
      6. Astrazeneca
      7. Bristol-Myers Squibb
      8. ELI Lilly and Company
  7. Analyst Views
  8. Future Outlook of the Market